CA2205872A1 - Acrylamide derivatives and process for production thereof - Google Patents

Acrylamide derivatives and process for production thereof

Info

Publication number
CA2205872A1
CA2205872A1 CA002205872A CA2205872A CA2205872A1 CA 2205872 A1 CA2205872 A1 CA 2205872A1 CA 002205872 A CA002205872 A CA 002205872A CA 2205872 A CA2205872 A CA 2205872A CA 2205872 A1 CA2205872 A1 CA 2205872A1
Authority
CA
Canada
Prior art keywords
ring
group
mmol
rom
mol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002205872A
Other languages
French (fr)
Inventor
Yasumichi Fukuda
Shigeki Seto
Yasuo Oomori
Hiroyuki Ebisu
Shiro Terashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Sagami Chemical Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2205872A1 publication Critical patent/CA2205872A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

An acrylamide derivative represented by general formula (1) e.g., methyl (S,S)-3,3'-[3,3'-(1,4-phenylene-diacryloyl)]bis[1-chloromethyl-5-hydroxy-7-trifluoromethyl-1,2,3,6-tetrahydropyrrolo[3,2-e]-indole-8-carboxylate, having a high cancer cell selectivity, a low toxicity, and a potent activity against solid tumors.

Description

SPECIFICATION

~, ACRS~LAMIDE DERIVATIVE:S AN~
PROCESS FOR PRODUCTION THEREOF

Technical Field The present invention ~elates to novel acrylamide derivatives, and optically active i~omerc and pharmaceutically aaceptable ~alts thereo~, which have antimicrobial and antitumor activities.

Background Techniques CC-1065, which.has antimicrobial and antitumor a~tivities., i8. disclosed.in J. Antibio$ics.: Vol.31, p..l211 (1978), and Vol.~4, p.lll9 (1981); and USP 4169888.
Duocarmycin A having a simil ~r structure, and analogues thereo~ are disclosed in W087/06265, EPo3i8056, and J.
~ Antibiotics: Vol.42, p.l229 (1989-), and JP-A-4-g9774.
. Deri~atives o~ CC-1065 are disclosed in EP0359454, JP.-A-6.0-lg~989;. and J~p~n~ç Rohyo.2.-5~2005... Derivatives o~
duocarmycins.are disclo~ed in JP-A-3-7287, ~P-A-3-12.837.9, EP0354583.,.and EP040674-9. All o~ these subs~.~n~s have a basic skeleton o~ n~tllral subst~n~s~ or deri~ed by chemical odi~ica$ion.o~..natural subst~nc~
Comp.ounds having $~o tetrahydLo~y loloindole skeletons in the molecule are included in the ~l A;~.~ 0~ JP-A-60-193989 (EP0154445) and Japanese Rohyo-2-502005 (W08804659). ~owever, no speci~iC compounds is mentioned, and no example is disclosed about the corresponding compounds. Compounds having a -R~-T-R~c- group as a bridging moiety (where R~, and R'~ are respectively a phenyl, heterocyclic, or benzene-condensed heterocyclic group which is substituted by a carbonyl group; T is a group of aminocarbonyl, carbonylamino, carbonylo~y, o~ycar~onyl, or the like) are disClOSed in ~apanese Rohyo 4-500664 (W09002746), and speci~ic example~ thereo~ include compounds having, as the bridging moiety, a car~onylbis(imino-lH-indole-2-carbonyl) group, 5,5'-[(1,2-dio~o-1,2-eth~nr~r~iyl)dia mino]bis-lH-indole-2-carbonyl group, or the like.
A compound having two 7-tri~1uoromethyl-8-methoxycarbonyl-1,2,3,6-tetrahyd~o~llolo~3,2-e]indole rings and carbonylbis(imino-lH-indole-2-carbonyl) group a8 a bridging moiety is disclosed by the inventors o~ the present invention (JP-A-6-116269).
However, the acry~ e derivatives of the present invention are not known.
The clinical therapy ~or C~nC~ includes surgical resection, radiotherapy with X-rays or the like, and ~h~motherapy with a chemotherapeutic. Of the-~e therapies,.only the chemotherapy with a chemotherapeutic is e~~ective against the cAn~r~s having spread over Yarious parts o~ the body, and t~m;nAl r~Anc~-~8. The chemotherapy, which is considered intrinsically to impose less burden to the patient, causes a~tually serious pains to the patient owing to the adverse strong side e~fect8. Although most o~ the current chemotherapeutic~ are e~~ective against le~lk~mi~ e~hibiting rapid cell growth, they are less ef~ectlve against solid cancer e~hi~iting slow cell growth. There~ore, the chemotherapy is not pre~erentially conducted for c~nC~ therapy.
In such a ~ituation of chemotherapy, the pre~ent invention intends to provide a compound which i8 e~ective selecti~ely against c~nc~ cells, e~ective also against solid tumors, and yet less toxic.

Disclosu e o~ the Invention A~ter comprehensive investigation to solve the above problems, a novel compound was ~ound, ~y the inventors o~ the present invention, which i8 e~~ective selecti~ely against cancer ~, less toxic, and e~ecti~e also against solid tumors.
The present invention provides acrylamide derivati~es, optical isomers thereo~, and pharmaceutiqAlly acce~table salts thereo~, and a process ~or production thereo~;
the acrylamide derivatives being represented by Genëral Formula (1): , - ~(1' (wherein X~ and a~ are independently a hydrogen atom, a halogen atom, an Amino group, an alkylamino group, an aminoalkyl group, a h~droxyl grou~ oR3 (R3 being a 1; ne~ or br~nch~A lower alkyl o~ Cl-C6 , or a substituted or unsubstituted aryl group), oCOR3 (R3 bein~ the same as above), or a li~ or branched lower alkvl o~ Cl-C6, and ~1 and x2 mav be linked to ether the ring A i~ a pyrrole ring, a ~uran ring, a thiophene ring, a benzene ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrA~; n~ ring, a biphenyl ring, a bipyridine ring, a bipyrimidine ring, a naphthalene ring, an anthracene ring, or an anthraquinone ring: and Rl and R are ;n~erendently:
a. B r . '~
~40 N

(R4 is a hydrogen atom, a protecting group ~or h~dro~yl, or a substituent decompo~able in ~ivo; Y is a halogen atom, an arylsul~onylo~y group, a lower alkylsul~onylo~y group, a haloalkylsul~onylo~y group, or an azide group;

(..B ~) i8 a condensed ring, or ( ~ ));
b. :~

~ t (('C ~) is a condensed ring or ( ~ ));
0~ the substi~uents ~fin~A as X~ and ~, the halogen atom includes a ~luorine atom, a chlorine atom, a bromine atom, and an iodine atom; the alkyl~m~no group in~~ n~ or br~n~-h~A Cl-C6 alkyl-substituted amino group such as methyl~m;no, dimethyl~;no~ ethy-~m;no, die~hyl~m;no, isopropylamino, and diisopropylaminO: the aminoalkvl ~rou~
includes linear or branched Cl-C6 alkvl ~rouP having an amin0 ~roup bonded thereto such as ~mi nom~thyl, 1-aminoethyl, 2-aminoethyl, 1-aminoisopropyl, 2-aminopropyl, and 3-aminoprOpyl; .
the substituted or unsubstituted aryl group includes unsubstituted aryl groups and aryl groups substituted with a halogen atom, an alkyl group, an amino group, an alkylamino group, an aminoalkyl group, a hydroxyl group, or the like such as chlorophenyl, methylphenyl, aminophenyl, methy~. ;nophen aminomethylphenyl, and hydroxyphenyl.
The wording "~ and ~ which m~y be li~ked togethexl' m~A n ~ an alkylene chain condensed with the ring A or an alkylene ring ContAi n; n~ one or two oxygen atoms, amino groups, an ester group, or a carbamoyl group, and bonded to the ring A, the e~ample including:

HN~,~ HN~ >

~N > 0~,0 O~ ~o. HN~ NH o~
H - O

HN~ HN~ HN~,o The condensed ring represented by (~ B ~) and (! C ¢.! incLudes condensed aromatic or nonaromatic hydrocarb~n rings or heteroavclic condensed rings such as M~ ~, O~ MsO2C
S MeO2C7~N~SS Meo2c~~~ M~~SS ~SS

H It H
The wording ~Isubstituent ~comrosable in vivo "
~A~ ~ a su~stituent giving a hydroxyl group by ~ nmposition in vivo, including.lower alkanoyl.groups, aryloyl groups, lower alkoxycarbonyl groups, substituted or unsubstituted aryloxycarbon~l groups, substituted or unsubstituted carbamoyl groups., and acyl residues.o~ a-amino.acids..
~ he.lower ~ noyl groups include speci~ically ~ormyl, acetyl, propionyl, butyryl, pi~aloyl, valeryl, and caproyl. The aryloyl groups include speci~ically benzoyl, phenylacetyl, and naphtoyl. The lower ~oYycarbonyl groups .include ~pe~; f ; CA 1 l y methoxycarbonyl, ~thoYycarbonyl, prop~y.~arbonyl, butoxycarbonyl, and hexyloxycarbonyl. The substituted or unsubstituted aryloxycarbonyl groups include ~ pheno~ycarbonyl., p-chlor.ophenoxycarbonyl., p-methoxyphenoxycarbonyl, p-aminophenoxycarbonyl, benzylo~ycarbonyl, p-chlorobenzyloxycarbonyl, p-methox~benzyloxycarbonyl, and p-Am;nohenzylo~ycarbonyl. The substituted.or unsubstituted carbamoyl groups include Specifically N-lower alkylcarbamoyl N N-di-lower alkylcarbamoyl, N-arylcarbamoyl, pyrrolidinylcarbonyl~ or substituted pyrrolidinylcarbonyl such as 3-(dimethyl ~m; no)pyrrolidinylcarbonyl; substituted or unsubstituted piperidinylcarbonyl such as 4-(dimethylamino)piperidinylcarbonyl and ~4-piperidinopiperidinyl)carbony.l; substituted or un~ubstituted 1-piperazinylcarbonyl such as (4-methyl-1-piperazinyl)carbony.l, ~4-[2-(dimethy~Amino)ethy~ -piperazin yl~carbonyl, [4-(2-(hydro~yethyl)-1-piperazinyl]carbonyl, and [4-[2-[2-(dimethyl Ami no~ethoxylethyl]-l-piper~ 7i nyl] carbonyl;
substituted or unsubstituted 1-morpholinylcarbonyl and ~y olidinylcarbonyl; and alky.l-substituted silyl. The acyl resif~ of ~-amino acids include acyl residues o~ glycine, ~l~n;n~j VA ~; nr~ c;ne~ isolel~c; nf~ ~ . serine, thr~o~;n~, cysteine,.methionine, ~spartic acid, glutamic acid, asparagine, gLu~m;n~, lysine., ar.g;n;n~,.phenyl~l~n;nr-, t~rosine, his~;~;n~r trQpto~n~, proline, and hy~O~yp oline with the amino group ~o~cted or protected by benzyloxycarbonyl, ~luo~enylmf~t-hyloxycarbonylr t-buto~ycarbonyl,. or t-h-e llke ..
~he arylsulfonylo~y groups include specifically benzf-ne~s~-lfc~nylo~;y, and tol!~ne~3ul~Dnylo~cy-~ ~he lower.
.alkylsul~onyl g~o~r.~.include ~eth~n~ul~on e~h~nr~.~ul~onyloxy., and propane~ul~ony.loxy. The haloalkylsul~onyloxy group8 include specifically tri~luorome~h~rosul~onylo~y, and trichlorOme~h~n~sul~onvlo~y.

Embodiments o~ the Invention The present invention provides a compound represented by General Formula (1) above produced throuah the process described below.
A ~arbo~ylic acid represen~ed ~y General Formula (2a):
R ~ Rs (2a) O X1 X2 o (where R is 0~; the rinq A X and X~ are the same as ~bove) i8 condensed with a compo.und represented by General Formula (4) or (5), or a salt.thereo~:

R4 ~ (4) ~ (5) (where ( B ¢)r ("C ¢)' R4, and Y are the same as abo~e) by use o~ a aon~n Q; n~ agent such a~ dicy.clohe~ylcarbodii_ide (DCC) and 3-ethyl-1-(3-dime~hy~ n opropyl)carbo~;i m;r~
l.y~lochloride. Otherwise, a carbo~y.lic acid h~ r~l a.
carbo~ylic acid imidazolide, an active.~ester o~ the carbo~ylic . .
acid, o~ a.m;~e~ or ~.ymmetric acid..anhydride~repre~.ented.by ~mlll a-(2b):
~ (2b) (where V is a reactive residue such as.a halogen.a~om, 1-imidazolyl, 4-nitropheno~y, and ~u~;n;m;doyloxy) i~ allowed to react with the above compound. Thereby a compound represented by General Formula (la~ or (lb) is produced:

R~ L ~ a) (1b) ~where the rina A. (:B ¢~ C ¢~. R . X . ~. and Y are the same as above). The condensation reaction can readily be conducted in the presence or absence o~ an organic base such as triethyl ~mi ne, diisopropylethyl~m; ne, pyridine, and dimethyaminopyridine; or an inorganic base such as sodium hydrogen carbonate, potassium carbonate, sodium hydride, and potassium hydride in a solvent such as dichloromethane, toluene, acetonitrile, N ! N-dimethyl~oramide, dimethylsul~oxide, and tetrahyd o~u~an, at a temperature ranging ~rom -20 to 50~C ~or a time ranging from 30 minutes to 48 hours.
In another method, a compound represented by General Form~ (lc) below:

H~~H (1c) ~where the ring A, (- B ~), Xl, X~, ~nd Y are the ~ame a~
above) is treated with a lower AlkAnoyl chloride, an ar chloride, a lower alkoxycarbonyl chloride, a ~ubstituted or unsubstituted aryloxycarbonyl chloride, an a-amino acid chloride, a substituted or unsubstituted carbam~oyl chloride, or an active es~er thereo~ to obtain a compound represented by General Fonmula (ld):

C r S ~ R4 ~ (where the ring A, ~ ~B ~)r R4, Xl, X~, and Y are the same as above). Thi~ reaction is conducted in the presence or absence o~ an organic base such as triethyl ~m; n~, diisopropylethylamine, pyridine, and dimethyl ~m; nopyridine;
or an inorganic base such as sodium hydrog~cA~honate, and ~ potassium carbonate, in an inert solvent at a temperature ranging ~rom -20 to 100~C, prefer_bly 0 to 50~C.
Further, the co_pound represented by G~nt-~Al Fo~m~l~ (lc) can be converted to the compound represented by General Fo~m~-l A ~lb) by a ring closure reaction in the presence o~ a base. Thi8 reaction is co~ncted by treating the compound represen~ed by General Form~ (lc) in the presence o~ 1 to 10 equivalent moles, pre~erably 1 to 5 eg~ivalent moles o~ an organic base such as a diaza$icyclo base, and triethy-Amine, or an inorganic ~ase such as sodium hydroxide, sodium hydride, and potas~ium carbonate in an inert solvent such as dichloromethane, toluene, acetonitriler N,N-dimethylform~mid~, dimethylsulfoxide, and tetrahydrofuran, or mix~ure thereof at -78 to 100~C, pre~erably from 0 to 50~C, for 10 minutes to 2a hours, pre~erably ~rom 20 minutes to 5 hours. The com~ound repre~ented by General Formula ~lb) can be converted to the compound represented by General Formula (lc) by treatment in the presence of hydrogen chloride, hydrogen bromide, hydrochloric acid, hydrobromic acid, toluenesulfonic acid, benzenesul~onic acid, methanesul~onic acid, trifluoromethansulfonic acid, hydrogen azide acid, or the like in an inert solvent such as ethyl acetate, dichloromethane, acetonitrile, N,N-dimethyl~ormamide, and tetrahydro~uran at a temperature ranging ~rom -20~C to the boiling point o~ the solvent, pre~erably ~rom 0 to 50~C. For this reaction, u~e of the an exce~sive amount o~ the.acid is ~ preferred ~or shor~n;n~ the reaction time.
Dialdehyde derivatives represQnted by General Form~-l A (9) -- O~C~C~O (g) R~l R~

where R1 is a l;n~ or br~n~h~ lower alkyl of C1-C6~ and another ~; A l~hyde represented by General Formula (7-):

Rt20C ~ CORI2 O o (7) CA 02205872 l997-05-22 ~here Rl2 is oRl3 ~Rl3 l~eing a ~~ n~7~ or hr~nr~hF~rl lower allc~l o~ Cl-C6), or a dialkylamino qroUD: R is a linear or br~n~.h~
lower alkyl o~ Cl-C6, or two Rl4 groups are 1inke~ toaether to ~orm a methylene, ethylene, or propylene group to form a ring~ can be produced through the steps shown below:

nlO n10 R 9 OC ~CoR9 H2N ~ ( ) Rlo~HN H ~R~~
MeO OMe ~irst step O O Second step MeO OMe (10~ (12) ~N ~ R1O R~Z1(13) R10 ~ N ~ N ~ Rl~ RI~Z2(14) o O Third ~tep O ~ O Fourth ~teP
MeO OMe R~ R
(4) (5) Rl~R (Z)(Z)R R10 R~ ~ ~ ~ N ~ R10~_ OHC ~ CHO
~O ~ OJ Fi~th step R~R~
Rl' Rl~ .
(15) (9) ~wh~re R9 i~ a hydroxyl aro~p or a reacti~e residue: Rl~ i~ a hydrogen atom, or a l;n~r. or.branched.lower.alkyl.o~ Cl-C6;
R~5 is methyl, ethyl, or benzyl; and Rll is the same as above).
(First Step) In this step, the compound rep.resented by General Formula (l0) is condensed ~ith the Gompound.represented.by General Form~ (ll) to produce the.compound ~er~e~ented..by General Fo~m~ (12).
Thi8 reaction can be conducted readily by con~ns~tion~ when R9 i8 0~, by uQe of a con~nsAtion a~ent such as dicyc~ohexylcarbo~; ; m; ~ (DC.C), and 3-ethyL-l-(3-diemthyl~minopropyl)carbodiimide hydrochloride, or, when R9 i8 a reactive re8idue such as a halogen atom, in the presence or absence o~ a ba8e such as pyridine, triethylamine, and dii~opropylethy- Ami n~, (Second Step) In this step, the compound represented by General Formula (12) is treated ~or ring closure to producé the compound repre~ented by General Formula (4). The ring closure reaction is conducted by treatment with polyphosphoric acid, polyphosphoric acid ester, sul~uric acid, thionyl chloride, or the like at a temperature o~ ~rom 0 to 100~C ~or 30 minutes to 24 hours.
(Third Step) In this step, ~he compound represented by General Form~ (4) i8 allowed to react with an organometallic reagent represented by General Form~ (13) below:

Rllzl ( 13 ) (where Z1 i8 Li, MgCl, or MgBr; and Rll is the same as above) to produce a compound represented by General Form~ (5).
T.his reaction can r~;ly be ~o~ ted by treatment in a solvent such as tetrahydro~uran, diethyl ether, dimetho~yethane, tol~ne, and h~n~, or a mixture thereo~ at a temperature o~ ranging ~rom -20 to 50~C ~or a time ranging ~rom 30 minutes to 24 hours.
(Fourth Step) In this step, the compound represented by General Form~ (5) is allowed to react with the compound represented CA 02205872 1997-0~-22 by General Fo 1~ (14):
Rls22 (14) (where Z i8 Cl , Br, I, OSo2c~3 ~ or (OSO2 ~Me); and R15 iQ
the same as a~ove). This reaction can readily ~e conducted in a sol~ent $uch aQ nitromethane, dimethyl~o~mr ;~, and dioxane, or without a ~olvent at a temperature ranging ~rom O
to 100~C ~or a time o~ from 30 minutes to 24 hourQ.
(Fi~th Step) In this step, the compound repreRented by General F~t~l 3 (15) is r~ to produce the ~ hyde derivative represented by General Formula (9). The r~~ n~ agent ~or this reaation inclùdes diisobutylaluminum hydride, lithium al~ hydride, sodium bis(methoxyetho~y)al~;~ hydride, sodium boronhydride, sodium cyanoborohydride, and lithium boron hydride. The reaction i Q con~cted in toluene, ether, diglyme, tetral,y~oru~an, methanol, or ethanol, or a mixture thereo~, and proceeds smoothly at a temperatt~e r~n~;n~ ~rom -78~C to 50~C.

Rl20C ~ CoR12 R1~Z3~16) Rl20C ~ COR~2 OHC ~ CHO
~0 OH Si~th ~tep ~~ ~~4 Seven h Step ~~ ~

In thi3 ~tep, the ~h~nol derivati~es represe~ted by General Formt~l~ (6) i8 alkylated by the compotmd represented by General Form~ (16) below:

*~Z3 - (16) (where Z is Cl, Br, I, OSO2C~3 ~ or (OSO2 ~M~); Rl~ i8 the same as abo~e) in the presence o~ caesium carbonate to prod~ce the compound repre~ented by General Fo 1 A (7). The reaction can readily be conducted in a sol~ent such as dimethyl~ormamide, dimethylacetamide, N-methylpyrro-i~o~, and dimethyl sul~oxide by use of 1 to 5 equivalents, pre~erably 2 equivalents o~ caesium carbonate, at a temperature ranging ~rom 0 to 100~C for a time of 30 minutes to 24 hours.
(Seventh Step) In this step, the co_pound represented by General Fs- 1 A (7) is r~ c~ to produce the dialdehyde derivative~
represented by General Formula (8). The redl~c;ng agent ~or this reaction include~ diisobutylal~;nl~m hydride, lithium alumin~ hydride, sodium bi~(methosyethoxy)Al ;- hy~i~e, and, sodium bis(2-methoxyethoxy)al~ ;num hydride/N-methylpiperA~tn~ and the like. This reaction i8 co~Aucted in toluene, ether, diglyme, tetrahydrofuran, or the like, or mi~Lu~e thereof. The reaction proceeds smoothly at a temperature of -78 to 50~C.
Rl~, which i~ a lin~Ar or brAn~h~ lo~er alkyl y ou~
o~ Cl-C6, include~ speci~ically methyl, ethyl, propyl, butyl, and i30~ o~yl.
Rll, which i8 a l;neA~ or brAnch~ lower alkyl y o~
of Cl-C6, includes specifically methyl, ethyl, propyl, butyl, and isopropyl.
R , which i8 a l;n~A~ or brAn~h~A lower alkyl y G~

o~ C6, inçludes speci~ically methyl, ethyl r nropyl, butyl, and i s opropyl.
The dialkylamino group includes specifically dimethylamino, diethylamino, dibutylamino, diisopropylamino, pyrrolidinyl, and piperidinyl.
R14 ~hich is ~ linear or branched lower alkyl ~rouP
o~ Cl-C6, includes speci~icafly methyl, ethyl, propyl, ~utyl, and isopropyl.
The compound, as the starting material in the present invention, represented by General Formula (2a) below:

R ~ (2a) o X1 X2 o ~where X~ , the ~inq A, and R5 are the same as above~ is an important interme~;~te o~ the present invention, and can be p~oduced by a method mentioned below as an example.
. y y~ y. ~\CoR16R~Rl6 X~ x2 Eighth step O X1 x2 o (17) (19) ~ Ninth step _ . .

OHC ~ CHO Tenth step R ~ ~s (20) (2a) In this step, the compound represented by General Form~ (17~ (in the ~ormula, Y is Br, I, or OSO2CF3; Xl, X , and the ring A are the 8ame as above) is allowed to react with the acrylic acid derivativeS represented by General Form~ 18~ ~in the ~ormula, Rl6 iS metho2y, ethoxy, or benzyloxy; y2 iS hydro~en atom, trimethyl~tannvl, or tributylstannyl) in the pre-~ence o~ a palladium catalyst ~or cross-coupling to produce the diacrylic acid ester derivatives represented by General Formula (19). This reaction can be conducted by a known method (for example, 'IJikken Kagaku Koza" (Te~tbook for E~perimental Chemistry), 4th Edition, pp.396-427, (1991), Maruzen).
(Ninth Step) -In this step, the diacrylic acid e~ter derivativesrepre.~ented by General Formula (19) is de-esteri~ied to produce the diacrylic acid derivative~ repre~ented by General.
Formula (2a). This reaction can be conducted by a known method (~Protective Groups in Organic S~nthesis~, pp.231-265 (1991), John Wiley ~ Sons).
(Tenth Step) In thi~ step, the ~ hyde derivati~es represented ,by General Formula (20) and malonic acid are condensed to produce the diacrylic acid derivati~es represented ~y Ge,neral Fo~m~l~,(2a). Thi~ reaction can be conducted by a known method.
T,he r~c~m~tes, and the optically active isomers o~
the compound~ repre~ented by General Fo~m~ (4) and (5) can be produced by a known method (for example, Tetrahedron Lett., Vol.27, p.4103 (1986); J. Med. Chem., Vol.37, p.232 (1994); BioMed. Chem. Lett., Vol.2, p.755 (1992); J. Am.
Chem. Soc., Vol.115, p.9025 (1993); J. Org. Chem., Vol.57, p.2878 (1992); JP-A-3-128379; and ~P-A-6-116269).
The compound represented by General Fo~m--l A (1) is useful a~ an antimicrobial and antitumor compo~ition singly or in co_bination with one or more known phA -c~u~ic~lly acceptable adjuvants. It can be do~ed orally in a ~orm of tablets, capsules, powders, grAnl~ , or ampules, or parenterally.
The parenteral ~ ;nQtration includes intravenous ~; n; stration, intraarterial ~m; n; stration, intraperitoneal a~m;ni8tration, hypo~r~i~ admini8~ration, intramuscular ~' ; n; stration, intrathoracic ~m; ni ~tration, and topical ~m; n; 8tration.
A ~. ~.o~d represented by General Fo l~ (1) or a salt thereof, ~or example, i8 dis801~ed in physiological nAl;ne, or an aqueous solution o~ glucose, ~nn;tol~ lactose or the like to prepare an a~ ~riate medical cômposition.
Otherwise, a salt of the compound represented by General FO~mlll A (1) is freeze-dried in a conventional mAnn~, and sodium chloride or the like is ~ thereto to prepare a powdery injection. This medical composition may contain a conventional additive for medicines, such as a p~A~Acoutically acceptable salt.
The dose o~ ~; n; stration depends on the age, and the sym~tom o~ the patient, and is ln the range o~ from 0.00001 to 100 m~/kg/day ~or m~mm~ ls includin~ humans. The administration is conducted, for e~ample, once or several times a day, or intermittently one to ~ive times a weak, or at inter~als o~ two to ~our weeks.
The effectiveness of the present invention is described below by re~erence to Examples without limiting the invention thereto Examples ~le 1 HO O O OH

To 13.5 mg (30 ~mol) o~ methyl (S)-3-t-butoxycarbonyl-1-chloromethyl-5-hydroxy-7-trifluoromethyl-1,2,3,6-tetrahydro~y~Lolo[3,2-e]indole-8-carbo~ylate, was added O.6 mL o~ 3M hydrogen chloride-ethyl acetate. The mi~ture was stirred at room temperature for one hour. Then the solvent was removed by distillation. The re~ulting residue was stirred with 3.3 mg (15 ~mol) o~ 3,'3'-(1,4-phenylene)diacrylic acid and 17.3 mg (90 ~mol) o~ 1-(3-dimethyl ~m; nopropyl)-3-ethylcarbodiimide hydrochloride in O.3 mL o~ anhydrous dimethyl~ormamide under an argon stream overnight. Water was added to the reaction mi~ture, and the ~esulting mixture was extracted with chloro~orm-methanQl ~,~"-.

CA 02205872 l997-05-22 (5: 1 ) . ~he extract was ~r; ~ over'anhydrous ~odium qul~ate.
The solvent was removed ~y distillation, and the residue was purified hy silica gel column chromatography (chloroform:methanol:acetone = 5:1:1) to obtain 3.3 mq (25~) of (srs)-3f3~-~3r3~ r4-phenylenediacryloyl)]-~is[l-chlorome thyl-5-hydroxy-7-tri~luoromethyl-l~2~3~6-tetrahydropyrrolo[3 2 - e~ indole -8-methoxycarbonyL~ in a yellow crystal ~tate.
~o~] 4D=-21~ (c=O . 20, tetr~hYdro:~uran~
N~ (DMSO d6) ~: 3.48(2EI,t,J=8Ez), 3.83(2~,d,J=8Hz), 3.88(6~,s), 4.28(2H,br), 4.40-4.49(4H,m), 7.30(2H,d,J=15Hz), 7,70(2E~,d,J=16Hz), 7.87~4~I,q), 8.11(2~,brs), 10.52(21I,br), 13 . 02 (2H,br) .
mE~lQ 2 MeO2C ~CI Cl ~ CO2Me S ~ ~
HO O o OH

To 13. 5 mg (30-~mol) of methyl (S)-3-t-~ y ~:arbonyl - l -chloromethyl~-5 -hydro~y- 7--trif l~ - thyl -1,2,3,6-tetrahyd~y. olo~3,2-e]indole-8-c~r~o~ylate, was A~A O.43 mL of 3M hydrogen chloride-ethyl acetate. The mixture was stirred at room temperature for 2 hours. Then the solvent was ~e~Gved by distillation. The resulting r~; A~ wa~ stirred with 4.8 mg (15 ~mol) o~ 3j3'-~9,10-anthracenediyl)d~acrylic acid and 17.3 mg (90 ~mol) of 1-(3-dimethyl ~m; nopropyl?-3-ethylcarbodiimide hydrochloride in O.3 .

mL ~~ anhydrous dimethyl~ormamide ~nder an argon stream overnight. Water was added to the reaation mixture, and the resulting precipitate was puri~ied by siliCa gel column chromatography (tetrahydrofuran:chloroform = 2:1) to obtain 3.7 mg (25%) o~ (s~s)-3r3l-[3~3l-(9~lo-anthracenediyl)diacr oyl]-bis[l-chloromethyl-5-hydroxy-7-tri~luoromethy~ 2l3l6-t etrahydro~y~lolo[3~2-e]indole-8-methoxycarbonyl] in a yellow crystal state.

CCY]D29=-144O (C=0.20~ tet~a~1YdrC)~I1~an) NMR (DM~O d6) ~: 3.56(2~,t,J=lO~z), 3.79-3.85(2H,m), 3.87(6H,s), 4.22-4.29(2H,m), 4.33-4 47(4H,m), 7.05(2H,d,J=16H
z), 7,66(4H,dd,J=4 and 7Hz), 8.22(2H,s), 8.37(4H,dd,J=7 and 4Hz), 8.55(2~,d,J=16Hz), 10.64(2H,s), 13.11(2~,s).
~m~le 3 F ~F3 In a 8;m~ m;~nn~t~~ 2.5 mg (15%) of~ (S~S)--3~3~--~3~
3 ~ - (5,8-dimethoxy-1,4-naphthalenediyl)diacryloyl]-bi8~1-chlor omethyl-5-h~d~o~y 7-trifluoromethyl-1,2,3,6-tetrahydLo~y ~olot3,2-e]indole-8-methoxycarbonyl] was obt~;ne~ ~rom 13.5 mg (30 ~mol) o~ methyl (S)-3-t-buto2ycarbonyl-1-chloromethyl-5-hydroxy-7-tri~luoromethyl-1,2,3,6-tetrahyd.~y,.olo[3,2-elindole-8-carbo~ylate and 4.9 mg (15 ~mo~) o~ 3,3'-(5,8-dimethoxy-1,4-naphthalenediyl)-diac rylic acid.
[a~D30=-56C (c=o .05, tetr~hydrofuran) NMR (DMSO d6) ~: 3.52(2~,dd,J=9 and ll~z), 3.80-3.87(2H,m), 3.88(6H,s), 3.89(6H,s), 4.23-4.31(2H,m), 4.40-4.47(4H,m), 6.77(2H,d,J=15Hz), 7.10(2H,s), 7.75(2H,s), 8.16(2H,s), 8.77(2H,d,J=15Hz), 10.54(2H,s), 13.06(2H,s).
~mrle 4 F3C ~ F3 In a si~ilar m~nn~, 4.1 mg (15%) o~ (S,S)-3,3'-[3, 3'-(2,3-(ethylenedio~y)-1,4-phenylene)diacryloyl]-bis[l-chlor omethyl-5-hydroxy-7-tri~1uoromethyl-1,2,3,6-tetrahyd o~y,~olo~3,2-e]indole-8-metho~Ycarbonyl] was obt~; n~ ~rom 26.9 mg (60 ~mol) o~ methyl (S)-3-t-buto~ycarbonyl-l-chioromethyl-5-hydro~y-7-trifluoromethyl-1,2,3,6-tetral~y~o~y~.olo~3 ! 2-e]indole-8-carbo~ylate and 8.3 m~ (30 ~mol) o~ 3,3l-(2,3-(ethylenedioxy)-1,4-phenylene)diacr ylic acid.
t~]D3~=-12~ (c-0.05. tetrah~dro~uran~
NMR (DMSO d~ 3.51(2H,t,~=lOHz) 3.79-3.85(2H,m), 3.88(6E,s), 4.23-4.32(2H,m), 4.38-4.44(4H,m), 4.46(4H,s), 7.25(2E,d,,J=16Hz), 7.52(2H,s), 7.89(2H,d,J=16Hz), 8.10(2H, 8), 10 . 56(2H,s), 13.07(2H,s).
~m~le 5 CA 02205872 l997-05-22 F3~ ~F~

In a similar manner, 2.4 mg (17~;~ of (~,S)-3,3'-~3, 3l-~2~3-~methylenedioxy)-l~4-phenylene)diacryloyl]-bi~[l-chlo romethyl-5-hydroxy-7-trifluoromethyl-1,2,3,6-tetrahydro~y~olo[3~2-e]indole-8-metho~ycarbonyl] was obtained from 13.5 mg (30 ~mol) o~ methyl (S)-3-t-butoxycarbonyl-l-chloromethyl-5-hydroxy-7-tri~luoromethyl-1,2,3,6-tetrahyd~o~y lolot3,2-e]indole-8-carbo~ylate and 3.9 mg (15 ~mol) o~ 3,3l-(2,3-(methylenedioxy)-1,4-phenylene)diac rylic acid.
r~, p3~=-12~ (c=O. 05 tetrahvdro~uran~
.NMR .(DMSO d,~ 3.52~2H,dd,J=9 and ll~z), 3.78-3.85(2H,m), 3.88(6~,~), 4.24-4.32.(2~,m), 4.32-4.45(4~,m), 6.38(2H,~), 7.28(2~,d,J=16Hz), 7.37(2H,q), 7.65(2Hfd!J=16Hz), 8.10(2H,~), lO . 58 (2H, 8), 13 .17 (2H, 8) .
~ m~le 6 - Fa~ F, In ~ .~;~n;lar m~nn~-~, 5.5 mg (20%) o~ (S,S)--3,3r--[3, 3 1 - (2, 3-diethy.1-1,4-phenylene).diacryloyl~-bi~.C1-chlorome~hyl-~ .5-hydro~y-7-tri~luoromethyl-1,.2,3,.6-tetrahydlo~y~lolo~3,2-e]i ndole-8-me.thoxycarbonyl.~ wa~. obt~; n~ ~rom 26.9 mg (60 ~mol) o~ methyl (s)-3-t-butoxycarbonyl-l-chloromethyl-5-hydroxy-7 23.

tri--fluoromethyl-l, 2, 3, 6--tetrahydropyrrolo ~3, 2--e] indole-8.--carb oxylate and 8.2 mg (30 ~mol) o~ 3,3'-(2,3-diethyl-1,4-phenyle ne)diacrylic acid.
[~D3l=-16~ (c=0.05, te~r~hvdrofurant NMR (DMSO d6) ~: 1.18(6H,t,J=8~Z), 2.85(4H,q,J=8~z), 3.51(2H,t,J=lOHz), 3.72-3.85~2H,m), 3.88(6H,s), 4.22-4.32(2~,m), 4.38-4.48(4H,m), 7.12(2H,d,~=16Hz), 7.78(2H,s), 7.99(2E,d,J=16Hz), 8.11(2~,s), 10.54(2H,s), 13.06(2H,s).
~mrle 7 MeO2C ~CI Cl ~ CO2Me - F3C ~ ~ OMe ~ ,CF3 HN~N~N~NH
Ho O MeO o OH

In a s;m;lA~ m~nn~r~ 2.1 mg (15%) of (S,S)-3,3'-[3, 3'-(2,5-dimetho~y-1,4-phenylene)diacryloyl]-bis[1-chloromethy 1-5-hydroxy-7-trifluoromethyl-1,2,3,6-tetrahyd~yllolo[3,2-e ~indole-8-methoxycarbonyl~ was obt~;n~ from 13.5 mg (30 ~mol) o~ methyl (S)-3-t-butoxycarbonyl-1-chloromethyl-5-hyd~o~y 7-trifluoromethyl-1,2,3,6-tetrall~dLo~y olot3,2-e]ind ole-8-carboxylate and 4.2 mg (15 ~mol) of 3,3'-(2,3-dimetho~y-1,4-phenylene)diacrylic acid.

r~l ~ =-s~o (c=~ . 05 r 1~ r~hydr4f~tlr~n) NMR (DMSO dç) ~: 3.52(2~rdd,J=8 and llHz) r 3.78 - 3.90(2H,m) r 3 88(6H,s), 3.98(6H,s) r 4.23-4.33(2H,m), 4.38-4.48(4~,m), 7.30(2H,d,J=16~z) r 7~53(2~r8) r 7~96(2~rdrJ=16~z)r 8~10(2Hr8) r 10.56(2~r~), 13.07(2~, 5) .

F~Am~le 8 MeO2C ~CI Cl ~ CO2Me F3C ~ MeO OMe ~ CF3 I IN~N~6N~NH
~O o o OH

In a similar manner, 1.1 m~ (8~) o~ (S,S)-3,3'-[3,3 '-(2~3-dimethoxy-l~4-phenylene)diacryloyl]-bi8cl-chloromethy 1-5-hydro~y-7-tri~luoromethyl-1,2,3,6-tetrahydropyrrolo~3,2-e ]indole-8-metho~ycarbonyl] was obt~; nr~ ~rom 13.5 mg (30 ~mol) o~ methyl (S)-3-t-butoxycarbonyl-1-chloromethyl-5-hydro~y-7-tri~luoromethyl-1,2,3,6-tetrahydrG~y olo[3,2-e]ind ~le-8-carboxylate and 4.2 mg (15 ~mol) O~ 3, 3 r -(2,5-dimethoxy-1,4-phenylene)diacrylic acid.
t~]~32=-26O (c=0.05, tetrahydrofuran) NMR (DMSO d6) ~: 3.51(2H,dd,J=9 and 10Hz), 3.79-3.94(2H,m), 3.88~6~,8), 3.90(6~,8), 4.24-4.33(2E,m), 4.39-4.49(4H,m), 7.31(2H,d,~=16Hz), 7.78(2H,8), 7.88(2~,d,J=16Hz), 8.11(2H,s), 10.57(2~,s),-13.08(2H,s);

... .
~rAmrle 9 MeO2C ~CI Cl ~ CO2A~e F,C _ ~ F, In a ~;m;lAr mAnn~, 1.7 mg (12%) o~ (S,S)-3,3'-[3, 3'-(1,1'-diphenyl-4,4'-diyl)diacryloyl]-bis[1-chloromethyl-5-hydro~y-7-tri~luoromethyl-1,2,3,6-tetrahyd o~y~olo[3r2-e]ind ole-8-methoxycarbonyl] wa~ obt~; n~ ~rom 13.5 m~ (30 ~mol) o~

. 25 methyl (s)-3-t-butoxycarbonyl-l-chloromethyl-5-h-vdro~y-7-tri~luoromethyl-1,2,3,6-tetrahydropyrrolor3~2-e]indole-8-carb oxylate and 4.4 mg (15 ~mol) o~ 3~3~ diphenyl-4r4l-di )diacrylic acid.
[~]D32=-360 (c=0.05, tetrahvdro~uran~
NMR (DMSO d6) ~: 3.50(2H,dd,J=9 and llHz), 3.78-3.90(2H,m), 3.88(6H,s), 4.23-4.32(2H,m), 4.38-4.52(4H,m), 7.29(2H,d,J=15H
~), 7.71(2H,d,J=15Hz), 7.84(4H,d,J=8Hz), 7.93(4H,d,J-8Hz), 8.11(2~,~), 10.56(2H,~), 13.07(2H,s).

mple 10 F~C ~F3 In a 8;milA~ ~nn~r, 3.0 mg (22%) o~ (S,S)-3,3'-t3, 3'-(1,4-napht.h~l~n~1iyl)diacryloyl~-bl~tl-chloromethyl-5-hydr oxy-7-tri~luoromethyl-1,2,3,6-tetrahy~v~yllolo[3,2-e]indole-8-metho~ycarbonyl3 was obt~; n~ ~rom 13.5 mg (30 ~mol) o~
methyl (S)-3-t-buto~ycarbonyl-1-chloromethyl-5-hydro~y-7-tri~luoromethyl-1,2,3,6-tetra~Ly~hv~y .olor3,2-e]indole-8-car~
o~ylate and 4.0 mg (15 ~mol) o~ 3,3'-(1,4-naphthalenediyl)dia crylic acid.
[~1 D --41~ (c=0.05 r tetrahydro~uran) NMR (DM~O d6) ~: 3.53(2H,t,J=lOHz), 3.78-3.92(2H,m), 3.88(6~,8), 4.25-4.34(2H,m), 4.45-4.54(4H,m~, 7.36(2H,d,J=15H
Z), 7.74(2H,dd,J=3 and 6Hz), 8.16(2H,s), 8.20(2H,s), 8.36(2H,dd,~=6 and 3Hz), 8.51(2H,d,J=15Hz), 10.60(2H,s), 13.09(2H,s).
mrle 1 1 F3C ~ ~ F3 In a similar manner, 2.3 mg (16%) o~ (S,S) _3, 3 r _ [3, 3l-(1,4-anthracr~nr~iyl)diacryloyl]-bis[l-chloromethyl-5-hydro ~y-7-tri~luoromethyl-1,2,3,6-tetrahydropyrrolo[3,2-e]indole-8-methoxycarbonyl] was obtained ~rom 13.5 mg (30 ~mol) o~
methyl (S)-3-t-buto~ycarbonyl-1-chloromethyl-5-hydroxy-7-tri~luoromethyl-1,2,3,6-tetrahydropyrrolo[3,2-e~indole-8-carb o~ylate and 4.8 mg (15 ~mol) o~ 3,3'-(1,4-anthracenediyl)diac rylic acid.
~]D32--360 (c=0.05, tetrahvdrof~ran!
NMR (DMSO d6) ~: 3.54(2H,t,J=lOHz), 3.78-3.93(2H,m), 3.89(6H,s), 4.27-4.36(2H,m), 4.46-4.57(4H,m), 7.43(2H,d,J=15H
z), 7.62(2~,dd,J=3 and 6Hz), 8.19(4~,8), 8.30(2H,dd,~=6 and 3Hz), 8.67(2~,d,~=15~z), 9.04(2H,s), 10.60(2H,s), 13.07(2H,s).
le 12 HO O ~ o OH

In a similar manner, 1.6 mg (4%) o~ (S,S)-3,3~-[3,3 '-(9,10-dihydro-9,10-dioxo-1,4-anthrac~nr~r~;yl)diacryloyl~-bis [l-chloromethyl_s_hydroxy-7-tri~lu~romethyl-l~2~3~6-tetrahydro~y. olo[3r2-e]indole-8-methoxyaarbonyl] was obtained from 40.4 mg (90 ~mol) o~ methyl (S)-3-t-butoxycarbonyl-l-chloromethyl-5-hydroxy-7-trifluoromethyl-1~2~3~6-tetrahydropyrrolo[3~2-e]indole-8-carboxylate and 15.7 mg (45 ~mol) o~ 3~3~-(9~lo-dihydro-9~lo-dioxo-l~4-anthracened iyl)diacrylic acid.
~ID32=-48O (c=0.05, tetrahvdro~uran~
NMR (DMSO d6) ~: 3.53(2H,dd,J=9 and 10Hz), 3.79-3.91(2H,m), 3.88(6H,s), 4.24-4.34(2H,m), 4.41-4.51(4H,m), 7.11(2H,d,~=16H
z), 7.95(2H,dd,J=3-and 6Hz), 8.10-8.19(4H,m), 8.21(2E,~), 8.53(2~,d,J=16Hz), 10.61(2H,s), 13.10(2H,s).
~mrle 13 MeO2C ~CI Cl ~ CO2Me F3C ~ ~ H
HO O o OH
In a 8;m;~ nn~ 2.4 mg (17%) o~ (S,S)-3,3'-~3, 3'-(2,2'-bipyridyl-5,5'-diyl)diacryloyll-~i8 [l-chloromethyl-5-hydroxy-7-trifluoromethyl-1,2,3,6-tetral~y~Lo~y olo~3,2-eli ndole-8-methoxycarbonyl] wa~ obt~; nr~r~ from 13.5 mg (30 ~mol) o~ methyl (S)-3-t-butoxycarbonyl-1-ahloromethyl-5-hydroxy-7-tri~luoromethyl-1,2,3~6-tetrahyd~o~y olo[3,2-e]indole-8-carb o~ylate and 4.4 mg (15 ~mol) o~ 3,3'-(2,2'-bipyridyl-5,5'-diy 1)diacrylic acid.
t~1D 2=_ 35~ (c=0.05, tetrahydro~uran?

NMR (DM~O de) ~ 3.sl(2H,dd,J=9 an~ lOHz), 3.77-3.92(2H,m), 3.88(6H,s), 4.25-4.33(2H,m), 4.39-4.55(4H,m), 7.47(2H,d,J-15H
z), 7.78(2H~d,J=lsHz)~ 8.13(2~,s), 8.51(4H,s), 9.08(2E,s), 10.60(2H,s), 13.09(2H,s)~
~m~le 14 MeO2C ~CI Cl CO2Me F3C ~?N~CF3 HO O O OH

In a similar manner, 3.5 m~ (27~) o~ (S,S)-3,3'-~3, 3'-(1,3-phenylene)diacryloyl]-bis[l-chloromethyl-5-hydroxy-7-tri~luoromethyl-1,2,3,6-tetrahydropyrrolo[3,2-e~indole-8-meth o~ycarbonyl] was o~t~i n~ ~rom 13.5 mg (30 ~mol) o~ methyl (S)-3-t-buto~ycarbonyl-1-chloromethyl-5-hydroxy-7-tri~luoromethyl-1,2,3,6-tetrahydl~yl~olo[3,2-e~indole-8-carb o~ylate and 3.3 mg (15 ~mol) O~ 3,3 r - (1,3-phenylene)diacrylic acid.
[a]D27--28~ (c=0.0~, tetrahydro~uran) NMR (DM~O d6) ~: 3.51(2H,dd,J-9 and lOEz), 3.75-3.93(2H,~), 3.88(6H, 5), 4.24-4.33(2H,m), 4.38-4.53(4H,m), 7.33(2H,d,J=16H
z), 7.52(1H,t,J=8Hz), 7.73(2H,d,J=16HZ), 7.88(2E,d,J=8Hz), 8.12(2H,~), 8.25(1H,s), 10.56(2H,8), 13.06(2~,~) le 15 MeO2C ~CI Cl ~ CO2Me F3C~_7 ~ ~CF3 HN ~ N~ N ~ NH

HO O . O OH

In a similar manner, 3.9 mg (30%) o~ (S,S)-3,3l-[3, 3~ r2-phenylene)diacryloyl]-bis[l-chloromethyl-5-hydroxy-7-tri~luoromethy~ 2r3t6-tetrahydropyrrolo[3~2-e]ind~le-8-meth oxycarbonyl] was obtained ~rom 13.5 mg (30 ~mol) o~ methyl (S)-3-t-butoxycarbonyl-1-chloromethyl-5-hydro~y-7-tri~luoromethyl-lr2r3r6-tetrahydropyrrolo[3r2-e]indole-8-carb o~ylate and 3.3 mg (15 ~mol) o~ 3~3~ r2-phenylene)diacrylic acid.
[~]D2B=-107~ (c=0.05 tetrah~dro~uran) NMR (DMSO d6) ~: 3.51(2H,t,J=9Hz), 3.75-3.92(2H,m), 3.87(6H,s), 4.22-4.32(2H,m), 4.38-4.50(4H,m), 7.16(2H,d,J=15H
z), 7.52(2H,dd,J=4 and 6Hz), 7.97(2H,m), 8.05(2H,d,J=15Hz), 8.11(2~, 8), 10 . 57(2~,Q), 13.06(2H,s).
F.~m~le 16 F3C ~F3 In a ~ nn~, 3.1 mg (10%) of (8lS~-3~3'-~3~
3'-(3,3"-(1,1':4',1"-terphenyl))diacryloyll-biQC1-chloromethy 1-5-hydroxy-7-tri~luoromethyl-1,2,3,6-tetrahydLo~yl olo[3,2-e lindole-8-methoxycarbonyll wa~ ob~;n~ ~rom 27.0 mg (60 ~mol) o~ methyl (S)-3-t-bu~oxycarbonYl-1-chloromethyl-5-hydro~y-7-tri~luoromethyl-1~2~3~6-tetrahyd~o~y olo~3,2-e]ind ole-8-carboxylate and 11.2 mg (30 ~mol) o~ 3,3'-(4,4'-(1,1l:4 ' 1"-terphenyl))diacrylic acid.

CA 02205872 l997-05-22 [Ct] D28=-19~ (C=0 05, tetrahydrofuran~

NMR (DMSO d6) ~: 3.51(2H,dd,J=9 and lOHz), 3.78-3.94(2H,m), 3.88(6H,S), 4.24-4.34(2H,m), 4.39-4.54(4H,m), 7.37(2H,d,J=15H
Z), 7 . 58 (2H, t,J=8Hz), 7 . 78 (2H,d,J=15HZ) ~ 7 . 81 (2H~d,J=8Hz), 7 . 83 (2H, d, J=8Hz), 7 . 92 (4H, s), 8 . 13 (2~, s), 8 . 18 (2H, s), lO . 56 (2H, s), 13 . 07 (2H, s) .
~m~?le 17 F3 ~ ~ ~;~F3 HO O O OH

In a similar m~nn~r, 4.9 mg (32%) of (S,S)-3,3'-~3, 3 ' - (4, 4"- (1,1~: 4 r,l"-terphenyl))diacryloyl]-bi~[l-chlorome~hy 1-5-hydroxy-7-tri~luoromethyl-1, 2 ~ 3,6-tetrahyd o~.lolot3,2-e ]indole-8-methoxycarbonyl] was obt~;ne~ from 40.5 mg (180 ~mol) o~ methyl (s)-3-t-butoxycarbonyl-l-chloromethyl-5-hydro y-7-tri~luoromethyl-1,2,3,6-te~rahyd o~yl olo[3,2-e]ind ole-8-carboxylate and 5.6 mg (15 ~mol) o~ 3,3'-(4,4'-(1,1':4' l"-terphen~l))diacrylic acid.

[~1D28=-17~ (c=0.05, tetrahydLo~ulan) NMR ~DMSO d6) ~: 3.50(2H,t,J=lOHZ), 3.79-3.93(2H,m), 3.88(6H, 8), 4.23-4.33(2H,m), 4.38-4.53(4H,m), 7.29(2H,d,~=16H
z), 7.72(2E,d,J=16Hz), 7.83(4E,d,~=8Hz), 7.88(4H,s), 7.93(4H,d,J=8Hz), 8.13(2H,s), 10.56(2H,s), 13.06(2H,s).

m~le 18 MeO2C ~CI Cl~ CO2Me Me ~ ~ ~ e In a similar manner, 8.8 mg (29%~ of~ (S S~--3,3l--C3, 3'-(1,4-phenylene) diacryloyl~-bis[l-chloromethyl-5-hydroxy-7-methyl-1,2,3,6-tetrah~ydrop~rrolo[3,2-e]indole-8-metho:~carbon yl] was obtained ~rom 31.6 mg (80 ~mol) o~ methyl (S)-3-t-butoxycarbonyl-1-chloromethyl-5-hydro~-7-methyl-1,2,3,6-tetrahyd o~y olo[3,2-e]indole-8-carbo~late and 8.7 mg (40 ~nol) o~ 3,3'-(1,4-phenylene)diacrylic acid.
[OllD28=-15~ (c=0 05. tetrah~drofuran) N~ (D~SO d6) ~: 2.61(6H,s), 3.41-3.47(2~,m), 3.80(6H,s), 3.77--3.90(2E~,m), 4.29--4.50(6E,m), 7.30(2~I,d,J=15Hz), 7.66(2~I,d,J=15Hz), 7.87(4H,s), 7.93(2H,s), 10.11(2H,s), 11.88(2H,s).

7mrie 19 H~ 7 ~ .H

In a s;m;lz~-~ m~nnl~r~~ 13.0 mg (5096) o~ (S,S)--3,3'--~3 ,3'-- (1,4-phenylene)diacryloyl~-bis[1-chloromethyl-5-hydro~y-8-methyl-1,2,3,6-tetrahydro~y~ olot3,2-e]indole] was obt~; n~
i~rom 27.0 mg (80 ~mol) of~ (S)-3-t-butoxycarbonyl-1-chloromethyl-5-hydro~y-8-methy~ 2~3~6-tetrahyd o~y~olo[3, CA 02205872 l997-05-22 2-elindole and 8.7 mg ~40 ~mol) o~ 3~3~ 4-phen~lene)diacry lic acid.
C~'] D =--42~ (c=0 05 . tetrahvdrof~an) N~ (DMSO d6) ~: 2.35(6H,s), 3.54--3.63(2H,m), 3~84-3~9l(2H~m) , 4.00--4.10(2H,m), 4 34--4 54(4E~,m), 7-03(2H,s), 7.29(2H,d,~J=l 6Hz), 7.65(2H,d,J=16Ez), 7.78(2H,s), 7.86(4H,s), 9.75(2H,s), 10 . 68 (2H, S) .
~mple 20 In a similar m~nn~ 1.5 mg (10%) o~ (S,S)-3,3'-[3, 3'-(1,4-phenylene)diacryloyl]-bistl-chloromethyl-5-hydroxy-1, 2-dihyd ~y lolo[3,2-a~carbazole] was obtained ~rom 14.9 mg (40 ~mol) o~ (S)-3-t-butox~carbonyl-1-chloromethYl-5-hydroxy-1,2-dil~y~L~ olo~3,2-a]carbazole and 4.4 mg (20 ~mol) o~ 3,3'-(1,4-phenylene)diacrylic acid.

t~]n28~~41~ (c=D.Q5. tetrahvdro~uran) NMR (DM~O d6) ~: 3.83(2H,dd,J=8 and llHz), 3.98-4.05(2H,m), 4.34-4.42(2H-,m), 4.53-4.64(4H,m), 7.18(2H,t,J=7Hz), 7.34(2H,d,~=15Hz), 7.39(2H,t,J=7~z), 7.51(2H,d,J=7Hz), 7.69(2H,d,J=15Hz), 7.90(4H,s), 7.91(2E,d,J=7Hz), 8.11(2H,s), io . 08(2E,s), 11.20(2H,s).

CA 02205872 l997-05-22 mrle 21 MeO2C ~Ci Cl ~ CO2Me HN~--N ~N~NH
~O O O OH
In a similar manner, 2.8 mg (30%) of (S,S)-3,3~ r 3~ r4-phenylene)diacryloyl~-bis[l-chloromethyl-5-hydroxy-l, 2~3~6-tetrahydropyrrolo[3~2-e]indole-8-methoxycarbonyl] was obt~i n~ ~rom 9.5 mg (25 ~mol) o~ methyl (S)-3-t-buto~ycarbonyl-1-chloromethyl-5-hydro~y-1,2,3,6-tetrahydro~yl.olo[3,2-e]indole-8-carbo~ylate and 2.7 mg (12.5 ~mol) o~ 3,3'-(1,4-phenylene)diacrylic acid.
~ --8~ (c=0.05 tetrahvdro~uran) NMR (DMSO d6) ~: 3.45-3.58(2H,m), 3.80(6~,s), 3.72-3.88(2H,m) , 3.94(2H,d,J-8.8Hz), 4.31-4.44(2H,m), 4.48(2H,d,~=8.8Ez), 7.31(2~,d,J=15~z), 7.67(2~,d,~=15Hz), 7.88(4H,s), 7.93(2~,d,J=2.9Hz), 7.97(2H,brs), 10.21(2~,~), 12.03(2H,~).

.~mrle 22 ~CI Cl ~
MeO2C ~CO2Me HN ~N~N ~ NH
HO O . O OH

In a 8;m;l~r m~nn~r~ 2.2 mg (6%) o~ (S,S)-3,3'-[3,3 l-(1,4-phenylene)diacryloyl~-bis[1-chloromethyl-5-hydroxy-1,2 ,3,6-tetrahydropyrrolo[3,2-e]indole-7-metho~ycarbonyl] wa~
obt~; n~ ~rom 38.1 mg (100 ~mol) of methyl (S)-3-t-butoxycarbonyl-1-chloromethyl-5-hydroxy-1,2,3,6-tetrahyd~opy ~olor3,2-e]indole-7-c~hoYylate and 10.9 my (50 ~mol) of 3,3'-(1,4-phenylene)diacrylic acid.

ta] D =+21~ (c=0.05, tetrahydrofuran) NMR (DMSO d6) ~: 3.87(6H,s), 3.90-3.99(2H,m), 4.02-4.16(4H,m) , 4.28-4.37(2H,m), 4.52-4.63(2~,m), 7.26(2H,d,J=15Hz), 7.22-7.30(2H,m), 7.66(2H,d,J=15Hz), 7.85(4H,s), 7.92(2H,8), 9.79(2H,~), 11.61(2H,s).
Re~erence ~mrle 1 TfO ~ OTf To 100 mg (0.62 mmol) of naphthoguinone, were ~dded 10.0 mg o~ 10~ p~llA~;um carbon, and 2 mL o~ anhydrous tetrahydkorulan. The mi~u~ wa3 stirred under a hydrogen atmosphere at room t~mr~ature ~or 2 ho ~8. Thereto, O.40 mL
(3.03 mmol) Of 2~4r6-col 1 ;~in~ and 0.26 mg (1.55 mmol) o~
triflic anhydride were ~e~ with ice cooling, and the mixture was stirred under an argon atmosphere at room temperature for 2 hours. The reaction misture was filtered, and the ~olvent was ~ Jved by distillation. The res;~e was dissolved in methylene chloride. The solution was wA~e~
~ucce~sively with water, lN hydrochloric acid, and saturated sodium chloride solution, and was dried over anhydrous sodium sulfate. The solvent was removed by distillation. The product was purified by silica gel column chromatography (h~n~:ethyl acetate = 10:1) to obtain 78.7 mg (30%) of 1,4-~i~(((tri~luoromethyl)sulfonyl)oxy)~-naphthalene in a state o~
a colorless oil.
Hiqh resolution mass spectrum as C12HcF6~6S2 Calculated: 423.9510 Found: 423.9512 Ref~erence E~eample 2 TfO ~ OTf ~ In a similar manner, 450 ma (66%) o~ 1,4-bis(((tri~luoromethyl)sul~onyl~oxy)anthracene was obtained ~rom 300 mg (1.44 mmol) o~ 1,4-anthraquinone.
Melting point 152.5-153.5~C
Elemental analysis as C16H8F6O6S2 Calculated: C, 40.51; H, 1.70 Found: C, 40.31; H, 1.54 Mass spectrum (m/z.): 474 (M) ~ Re~erence ~mrle 3 TfO ~ OTf MeO ~ OMe In a ~jmilAr m~nner, 163 mg (15~) o~ 1,4-bis(((trifluoromethyl)~ulfonyl)o~y-5~8-dime~hoxynaphthalene was obt~;n~ ~rom 500 mg (2.29 mmol) Of 5,8-dimethoxynaphthoquinone.
Melting point 145.5-146.5~C

Elemental analysis as C~ OF6O8S7 Calculated: C, 34.72; H, 2.08 Found: C, 34.88; H, 1.82 Mass s~ectrum (m/z): 484 (M ) Re~erence E~ample 4 TfO ~ OTf MeO OMe In a similar manner, 218 mg (84~) o~ 1,4-bis(((tri~1uoromethyl)sul~on~1)oxy)-2,3-dimethoxYbenzene wa~
obt~;nr-r~ ~rom 100 mg (0.59 mmol) o~ 2,3-dimethox~benzoquinone, ~ High resolution masg spectrum as CloH8F6O~S2 Calculated: 433.9565 Found: 433.9564 Re~erence,~mple 5 TfO ~ OTf In a simil~ m~nn~r, 567 mg (84%) of 5,51-bis(((tri ~luoromethyl) sulfonyl ) ox y) -2,2'-bipyridyl was prepared ~rom 280 mg (1.49 mmol) o~ 5,5'-dihydroxy-2,2l-bipyridyl.
Melting point 158.0-162.0~C
Elemental analysis as Cl2H6F6N2O6S2 ~ Calculated: C, 31.87; H, 1.34; N, 6.19 Found: C, 31.72; H, 1.14; N, 6.40 Mass spectrum (m/z): 452 (M~) Reference Example 6 EtO2C~ CO2Et ~ ' .
In 5 mL o~ anhydrous dimethyl~ormamide, were suspended 30.0 mq (71 ~mol) o~ 1,4-bis(((trifluoromehyl)-sul~
onyl)o~y)naphthalene~ 0.04 mL (O.29 mmol) o~ triethylamine, 0.16 mL (1.5 mmol) o~ ethyl acrylate, 2.9 mg (7.0 ~mol) of 1,3-diphenylphosphinopropane, and 1.6 mg (7.1 ~mol) o~
palladium acetate. The su~pension was stirred overnight ~nder an argon abmo~phere at 80~C. Thereto, methylene chloride was added. The mixture was washed successively with 5% hydro~hloric acid, water, saturated sodium chloride solution, and dried over anhydrous sodium sulfate. The -~olvent was removed by distillation. The re~ulting r~si~
was puri~ied by silica gel column chromatography (methylene chloride:h~n~ = 1:1) to obtain 19.5 m~ t85%) o~ ethyl 3,3'-(1,4-naphthalenediyl)diacrylate in a yellow crystal state.
M~lting point 84.0-87.0~C
Elemental analysis as C20~20O~
Calaulated: C, 74.06; E, 6.21 Found: C, 73.89; ~, 6.21 Mass spectrum (m/z): 324 (k~) Re~erence Example 7 ~ EtO2C~r C02Et ~ .

CA 02205872 l997-05-22 In a ~;m;l~ ~nn~ 169 mg (71ff) o~ ethyl 3,3'-(1,4-anthracenediyl)diacrylate was obt~;~eA ~rom 300 mg (0.63 mmol) o~ 1,4-bi~(((tri~luoromethyl)sul~onyl)-oxy)anth~acene Melting point 98.5-99.5~C
Elemental analysis as Cz4H2204 Calculated: C, 76.99; H, 5.92 Found: C, 76.76; ~, 6.04 Mass spectrum (m/z): 374 (M) Re~erence ~mrle 8 EtO2C~r C0 0~0 6~
In a ~;m;l~ m~nn~r, 49.0 mg (61%) o~ e~h~l 3,31_ (9,10-dihydro-9,10-dioxo-1,4-anthracenediyl)diacrylate wa~
ob~i n~ ~rom 100 mg (0.20 mmol) o~ 1,4-bis(((tri~luoromethyl)sulfonyl)oxy)-9,10-dihydro-9,10-di,o,~oan thracene.
Melting point 222.5-224.5~C
Elemental analysis as C2~20O6 Calculated: C, 71.28; H, 4.98 Found: C, 7i.09; H, 4.93 Mass spectrum (m~z): 404 (M~
Re~erence ~m~le 9 ~ EtO2C~r C02Et MeO ~ OMe ' 39 In a s;mil~ m~nnr-~ 219 ~g (92%) of ethyl 3t3r-(5,8-dimethoxy-1,4-naphthalenediyl)diacrylate was obtA; n~
~rom 300 mg (0.62 mmol) o~ 1,4-bis(((tri~luoromethyl)-sul~ony l)oxy)-5,8-dimethoxynaphthalene.
Melting point 119.0-122.0~C
Elemental analysis as C22H2406 Calculated: C, 68.74; ~, 6.29 Found: C, 68.50; H, 6.27 Mass spectrum (m/z): 384 (M) Re~erence ~mrle 10 ~C~ ~r In a sim;l~ m~nne~ 54.3 mg (84%) o~ ethyl 3,3'-(2, 2 ~ - bipyrldyl - 5, 5 r - diyl) diacrylate was obt~; n~ ~rom 83. 2 mg (0.18 mmol) of 5,51-1,4-bi8(((tri:f~1uoromethyl)8ul~on:yl)-y) -2, 2 ' -bipyridyl .
Melting point 173.5-175.0~C
Elemental analysis as ~ oN204 C~ ted: C, 68.17; H, 5.72; N, 7.95 Found: C, 67.89; H, 5.64; N, 7,93 Mass spectrum (m/z): 352 (M~) Re~erence ~mple 11 EtO2C~ CO2Et MeO OMe In 2.3 mh o~ anhydrous dimethyl~ormamide, were su8pr-nrl~ 200 mg (0.46 mmol) o~ 1,4-bis(((trifluoromethyl)-su -l~onyl)o~y)-2,3-dime~hoxybenzene, a~d 58.5 m~ (1.38 mmol) o~
lithium chloride. Gaseous argon was blown therein to remove air. Further thereto, 16.1 mg (23 ~mol) o~
bis(triphenylphosphine)palladium dichloride was added. The mi~ture was ~tirred at 100~C ~or 30 minutes. Thereto, a solution o~ 537 mg (1.38 mmol) o~ ethyl 3-(tributylstannyl)acrylate in 0.5 mL o~ anhydrous dimethyl~ormamide was added. The mixture was stirred at 100~C ~or 30 minutes. Methylene chloride was added thereto, and the mixture was washed successively with water! and 5~
potassium ~luoride, and dried oYer anhydrous sodium sulfate.
The solvent was removed by distillation. The resulting residue was puri~ied by silica gel column chromatography (ethyl acetate:he~ne = 1:6) to obtain 18.6 mg (14%) o~ ethyl 3,3'-(2,3-dimetho~y-1,4-phenyl~ne)diacrylate in a colorless prism crystal state.
Melting point 88.5-89.5~C
Elemental analysis as Cl8H22O6 Calculated: C, 64.66; H, 6.63 Found: C, 64.45; H, 6.66 Mass speatrum (m/z): 334 (Mt) Re~erence ~rle 12 H02C ~ r C02H
. ~ .
In 2 mL o~ ethanol, were dissol~ed 115 mg (0.35 mmol) o~ ethyl 3,3'-(1,4-naphthalenediyl)diacrylate and 196 mg (3.~9 mmol) o~ potassium hydroxide. The solution was re~luxed ~or 2 hours. ~hereto, lN hydrochloric acid was added to bring the solution to pH=l. The deposited crystal was wa~hed successively with water, and ethanol, and dried to o~tain 90.2 mg (95%) -o~ 3,3'-(1,4-naphthalenediyl)-diacrylic acid in a yellow crystal state.
Melting point 350.0-355.0~C
High re~olution mas~ spectrum a~ Cl6Hl204 Calculated: 268.0736 Found: 268.0743 Re~erence E~ample 13 H02C~/~ C02~1 .~

In a ~;~;1A~ m~nn~, 152 mg (89%) o~ 3,3'-(1,4-anthrAq~neA;yl)diacrylic acid was obt~;n~ ~rom 200 mg (0.53 mmol) o~ e~hyl 3,3'-(1,4-anthr~q~n~;yl)diacrylate.
Melting point 328.5-338.0~C (~omposed) . H_gh resolu~.on mass ~pea~om as C20H,40~ :
Calculated: 318.0892 Found: 318.0894 Re~erence E~ample 14 HO2C~J~ CO2~1 0~0 .~

In a s;mi~r mAnne~/ 215,mg (100%) o~ 3,3'-(9,10-dihydro-9~lo-dioxo-l~4-anthracenediyl)diacrylic acid was obtained ~om 250 mg (0 62 mmol) o~ ethyl 3,3'-(9,10-dihydro-9,10-dioxo-1,4-anthracenediyl)diacrylate.
Melting point 323.0-338.0~C (decomposed) Elemental analysis as CzOHl2O6 Calculated: C, 68.97; H, 3.47 Found: C, 68.71; H, 3.31 Reference ~m~le 15 H02C ~r C02H

MeO ~ OMe In a .s;milA~ m~nn~, 79.5 mg (93%) o~ 3,3'-(5,8-dimethoxy-1,4-naphthalenediyl)diacrylic acid was obt~; ne~
~rom 100 mg (0.26 mmol) of ethyl 3,3'-(5,8-dimethoxy-1,4-naph thalenediyl)diacrylate.
Melting point 290.0-299.5~C (~co~ro~ed) High resolution mass spectrum a~ Cl8Hl5O6 C~ ted: 327.0869 Found: 327.0934 Re~erence ~mrle 16 H02C ~y_ ~;~/~ C02H

In a 8;m;l~r m~nn~r~ 73.8 mg (88%) o~ 3,3'-(2,2'-~i .
pyridyl-5,5'-diyl)diacrylic acid was obt~;n~ ~rom 100 mg (O.28 mmol) o~ ethyl 3,3l-(2,2'-bipyridyl-5 ! 5'-diyl)diacrylate.
Melting polnt 447.~-454.0~C (~omposed) CA 02205872 l997-05-22 ~igh resolution mass ~pectrum as Cl6~l2N~O~
Calculated: 297.0875 Found: 297 . 0875 Re~e~ence Example 17 HO2C~ co2 MeO OMe In a simil~r manner, 3~.3 mg (98%) o~ 3,3'-(2,3-dimethoxy-1,4-phenylene) diacrylic acid was obt~ i ne~ from 44.5 mg (O . 13 mmol? o~ ethyl 3,3l-(2,3-dimetho2y-1,4-phenylene)dia crylate Melting point 304. 0 - 315 . 5~C (decomposed) ~igh resolution mass spectrum as Cl4Hl406 Calculated: 278.0790 Found: 278.0802.
Re~erence ~mrle 18 H02C ~r C02H

In a ~ nn~, 161 mg (96~) o~ 3,3'-(9,10-anthracenediyl)diacrylic acid was obt~; n~ ~rom 200 mg (0.53 mmol) o~ ethyl 3,3'-(9,10-anthracenediyl)diacrylate.
Melting point 310.5-319.0~C (decomposed) High resolution mass spectrum as C20Hl404 Calculated: 318.0892 Found: 318.0915 Reference EYample 19 OffC ~ C~O
MeO OMe To 13.6 g (47.1 mmol) of sodium bis(2-metho~yetho~y)all ;nllm hydride (70~ toluene solution), was A~e~ a solution of 5.20 g (51.9 mmol) of N-methylpiper~ine in 23 mL o~ anhydrous toluene to prepare a reagent.
Separately, 3.00 g (11.8 mmol) o~ methyl 2,3-dimetho~y-1,4-benzenedia~hoYylate was dissolved in 120 mL of anl~d~Ou8 toluene. ~o this solution, the above reagent was A~A at a temperature of from -20 to -17~C, and the mixture was stirred ~or 10 minutes. Water was A~ to the reaction mi~ture, and the insoluble matter was L~o~ed there~rom. The solution ~as w~he~ s1~cc~sively with lN hydrochloric acid, water, saturated sodium chloride solution, and was dried over anhydrous sodium sulfate. The solvent was .~ov~d by distillation, and the product was puri~ied by 8;1;aA gel chromatography (methylene chloride) to obtain 1.84 g (80~) o~
2,3-methoxy-1,4-benzenedir~rh~l~hyde in a colorless crystal state.
Melting point 99.5-100.5~C
Elemental analysis as CloHl004 Calculated: C, 61.85; H, 5.19 Found: C, 61.74; H, 5.18 Mass speatrum (m/z): 194 (M~) CA 02205872 1997~05~22 Re~erence E~ample 20 ~

OHC ~ CHO
0\ 0 In a similar manner 371 mg (16%~ o~ 2.3-(ethylenedioxy~-l r 4-benzenedicarbaldehyde was obtained ~rom 3.00 g (11.9 m.~ol) o~ methyl 2l3-(ethylenedioxy)-1,4-benzenedicarbo~ylate.
Meltin~ point 13~.0-140.5~C
Elemental analysis as C1~ROA
Calculated: C, 62.50; H~ 4.20 Found: C, 62.47; H, 4.26 M~8 s~ectrum lm/z): 192 (M
Re~erence Example 21 OHC ~ CHO
O ,~0 In a similar m~nn~ 1.52 g (68~) o~ 2.,3-(methyl~n~A;oxy)-l~4-benzenedicA~h~lA~hyde was obt~;ne~ ~rom 3.00 g (12.6 mmol) o~ methyl 2,3-(methyl r~nr~r~; 02y) -1 r.4~
benzenedicarbo~ylate. ..
Melting point 151.5-152.0-~C' ~Elemental analy~is as C~H~O~

Calculated: C, 60.68; H, 3.39 F~und: C, 60.59; H, 3~40 Mas~ ~ectrum (m/z): 178 (M ) Re~erence ~mrle.22 CA 02205872 l997-05-22 HO2C~ CO21 1 MeO OMe A liquid s~s~enslon com~osed o~ 1 00 ~ (5.15 mmol~
o~ 2~3-dimethQ~y-l~a-benzenedicarbaldehyde~ 2,37 g (22.8 mmol) o~ malonic acid, 0.1 mL o~ piperidine, and 7.0 mL o~
pyridine W2S re~luxed for 16 hours. The reaction mixt~re W25 aooled with ice, and the pH was adjusted to 2 by addition o~
lN hydrochloric acid. The deposited crystalline matter was collected by filtration, and was washed successively with water, ethanol, and methylene chloride to obtain 1.34 g (94%) o~ 3,3'-(2,3-dimethoxy-1,4-phenylene)diacrylic acid.
Re~erence Example 23 HO2C ~r C021 f 0\ 0 In a simil~ manner, 1.39 g (96~) o~ 3,3'-(2,3-(eth ylenedioxy)-1,4-phenylene)diacrylic acid was obt~i n~ ~rom 1.01 ~ (5.26 _mol) o~ 2,3-(ethylenedioxy)-1,4-benzenedicarbaldehyde.
Melting point 344.5-348.5~C
High resolution mass spectrum as Cl4Hl206 Calculated: 276.0634 Found: 276.0634 Re~erence ~mple 2 4 H02C~ co2 ~=( O ~0 In a si~ilar manner, 1.39 g (94%) of 3,3'-(2,3-(mQt hylenedioxy)-1,4-phenylene)diacrylic a¢id wa~ obtA; n~tl from 1.00 g (5.61 mmol) of 2,3-(methylen~io~y)-1,4-benzenedi~A''hA1~hyde.
Melting point 334.0-338.0~C
~igh resolution mass spectrum as Cl3E10O6 Calculated: 262.0477 Found: 262.0462 Reference Example 25 2C y~rco Et ~t In a ~imilar manner, 62.6 mg (74%) of 3,3'-(2,3-diethyl-1,4-phenylene)diacrylic acid wa~ obt~;ne~ from 59.8 mg (0.31 mmol) Of 2,3-diethyl-1, 4 - h~n 7~ne~; ~ rhA 1 ~hyde .
Melting point 264.0-268.0~C (~ecQ~osed) Eigh re~olution mass spectrum as Cl6El8C~
Calculated: 274.1205 Found: 274.1160 Reference ~YAmrl~ 26 HO2C~ co2~

In a similar ~nn~ 96.4 mg (93~) Of 3~3' - (4t4'r-(1 ,1':4~, 4~l-terphenyl))diacrylic acid wa~ obtA; ~ ~rom 80 mg (0.28 mmol) of (1,1~:4~ 4"-terphenyl))-4,4"-dic? ~hA ldehyde.
Melting point 340.0-345.0~C

Elemental analysis as C24~18O4 ~lq~ ted: C, 77.82; H, 4.39 Found: C, 77.72; ~, 5.10 Re~erence r---~ le 27 ~02C C02H

In a 8; ;li~ n~e~ 1.06 g (9596) of 3r3~~(3r3r~~(1r 1':4', 4"-terphenyl))diacrylic acid was obtA; ne~ from 859 mg (3.00 mmol) o~ (1,1':4', 4"-terphenyl)-3,3"-dicarbosyaldehyde.
Melting point 337.0-343.0~C
Eigh resolution mass spectrum as C24E170~ -Calculated: 369.1127 Found: 369.1214 Re~erence Example 28 MeO2C~C02Me MeO OMe In 50 mL of a~lyd~o~s dimethyl~ormamide, 5.00 g (22.1 mmol) o~ methyl 2,3-dihydrosy-1,4-benzenedic~hoYylate was dissolved. Thereto, 17.3 g (53.1 mmol) of cesium carbonate was ~o~. The solution was stirred under an argon atmosphere at room temperature ~or 30 minutes. Further thereto, 3.31 mL (53.2 mmol) o~ methyl iodide was A~Ao~, and the mi~Lu~e was stirred at room temperature ~or 2 hours. The reaction solution was concentrated at a r~--ce~ pressure.
M~thylene chloride was A~e~ thereto. ~he mixture was wA~h~
successively with water, and a saturated sodium chloride solution, and was dried over anl-ydLous sodium sul~ate. The solvent wa~ removed there~rom by di~tillation to obtain 5.55 ~ (99~) o~ methyl 2r3-dimethoxy-lr4-benzenedicarboyylate~
Mass spectrum (m/z~: 254 (M~
Re~erence Example 29 MeO2C~ CO2Me O O

In a sim;~ manner, 5.54 g (99%) o~ methyl 2,3-(ethylenedioxy)-1,4-ben~enedicarbo2ylate was obtained ~rom 5.00 g (22.1 mmol) of methyl 2,3-dihydroxy-1,4-benzenedicarboxylate.
Melting point 107.5-110.0~C
Mass ~pectrum (m/z): 252 (M~
Re~erence ~Y~mrle 30 MeO2C~ CO2Me 0~0 In a ~m;l~ m~nn~ 5.14 g (98~) o~ meth~l 2,3-(methyl~n~;02y)-1,4-benzenedicarboxylate ~a~ obt~;n~ ~rom 5.00 g (22.1 mmol) o~ methyl 2,3-dihydroxy-1,4-~enz~n~A;carbo2yiate.
Meiting point 208.0-210.0~C
~a88 spectrum (m/z): 238 (M~
Re~erence ~mrle 31 Me M~
Me ~ H H ~ Me HO ~ ~ OH

MeO OMe In 8 mL o~ anhydrou.~ methylene chloride, was dissolved 6.06 g (68.0 mmol) of 2-amino-2-methyl-1-propanOl.
Thereto, a solution o~ 4.47 g (17.0 mmol) of 2,3-dimetho~y-1,4-benzenedicarbo~ylic chloride in 8 mL of anhydrous methylene chloride was added by keeping the inner temperature at 5-10~C, and the mixture was stirred at room temperature ~or 2 hour~. The reaction mixture was filtered, and washed with water. The ~il~rate and the wash water were combined and concentrated under a r~c~ pre~sure. Methylene chloride was added to the obtained residue, and the mixture was dried over anhydrous sodium sul~ate. The solvent wa~
removed. The product was recrystallized ~rom benzene to obtain 6.27 g (100~) o~ N,NI-bi~(2-hydroxy-l,l-di~ethylethyl )-2~3-dimethoxy-l,4-phenylenedicar~o~amide in a colorless prism crystal state.
Melting point 151.0-153.0~C
Elemental analysis as C18H28N2O6 Calculated: C, 58.68; H, 7.66; N, 7.60 Found. C, 58.65; H, 7.79; N, 7.44 Mass spectrum (m/z): 368 (k~) Re~erence ~m~le 32 O>~N~Me MeO OMe To 6.00 g (16.3 mmol) o~ N~Nl-bis(2-h~droxy-l,l-dimethylethyl)-2,3-dimethoxy-1,~-phenylenedicarbo~amide,.was A~eA 7,0 rnT. (96.0 mmol) o:~ thionyl chloride. The mixture was stirred at room temperature ~or 3 hours. Further thereto, 7.0 mL (96.0 mmol) of thionyl chloride was added, and the mixture was stirred at room temperature for one hour.
The reaction solution was poured into 50 mL of ether. The supernatant liguid was remo~ed by decantation. Aqueous 10%
sodium hydro~ide solution was added to the re5idue to bring the p~ to 8. It was extracted with ether, and was dried over anhydrous sodium sul~ate. The solvent was ~m~ed by di~tillation, and the residue was puri~ied by silca gel column chromatography (methylene chloride:e~hanol = 20:1) to obtain 2.52 g (47%) of 2r2~-~2~3-dimetho~y-lr4-pheny-lene)-bis (4,4-dimethyl-2-oxazoline) in a colorless cry~tal s~ate.
Melting point 84.5-85.5~C
Elemental analysis a5 Cl8H24N2~4 Calculated: C, 65.04; H, 7.28; N, 8.43 Found: C, 64.96; ~, 7.16; N, 8.41 Mass spectrum (m/z): 332 (M') Re~erence ~mrle 33 Me; ~ Me ~t ~t In 20 mL o~ anhydrou~ tetrahydLo~u~an, was dissol~ed 2.00 g (6.02 mmol) o~ 2,2'-(2,3-dimethoxy-1,4-pheny lene)-b~4,4-dimethyl-2-oxazoline). Thereto, 16.4 mL o~
O.92M ethylmagnesium bromide ~olution (15;1 mmol) in tetrahydro~uran wa~ added dropwi~e with ice cooling in 30 minutes, and the mi~ture wa~ stirred at room temperature for 2 hours. To the reaction liquid, were added successively 10 mL o~ aqueous saturated ammonium chloride solution and 30 mL
o~ water. The product was e~tracted ~rom the mixture with ether, washed with a saturated sodium chloride solution, and dried over anhydrous sodium sulfate. The solvent wa~ removed by distillation. The residue was puri~ied by silica gel column chromatography (ethyl acetate:he~n~ = 2:1) tolobtain 1.98 g (100%) o~ 2,21-(2,3-diethyl-1,4-phenylene)-bi~(4,4-dim ethyl-2-o~azoline) in a colorle~8 prism crystal state.
Mel~ing point 49.0-50.0~C
Elemental analysis as G>u~uN2o2 Calculated: C, 73.14; H, 8.59; N, 8.53 Found: C, 72.97; ~, 8.56; N, 8.46 Ma8S ~pectrum (m/z): 328 (M+) Re~erence ~m~le 34 ~ , Et Et To 1.86 g (5.66 mmol) o~ 2,2'-~2,3-~ie~h~ 1,4-ph~n ylene)-bis(4,4-dimethyl-2-o~azoline), were added 5.0 mL o~
nitromethane and 7.0 mL (122 mmol) o~ meth~l iodide. The mixture was stirred at 80~C ~or 4 hours. The reaction liquid was pou~ed into 30 mL o~ ether. The deposited cryst~ll ;n~
matter was collected by ~iltration, and was recryst~ ed ~rom ethanol ~o o~tain 2.62 g (76%), o~ 2,2'-(2,3-diethyl-1,4-phenylene)-bis(3,4,4-trimethyl-2-o~azolium iodide).
Meltinq point 281.0-285 0~C
Elemental analysis zs C2q~3~ 2N~O2 Calculated: C, 43,15; H, 5.60; N, 4.57 Found: C, a3 05; H, 5 41; N, 4 72 ~ass spectrum (m/z~: 329 (Mt~1-2MeI~
Reference ~mrle 35 OHC ~ CHO
Et Et In 50 mL o~ ethanol, was susp~nt~-~ 2. 45 g (4 . 00 mmol) o~ 2,2'-(2,3-diethyl-1,4-phenylene)-bis(3,4,4-trimethy 1-2-o~azolium iodide). Thereto, 770 mg (20.4 mmol) o~ sodium boron hydride was added dropwise with ice cooling in one hour, and the ml~ture wa~ stirred at 5~C ~or 3 hours ~ydrochloric acid ~2N) was added to the reaction liquid. The product was e~tracted with ether ~rom the reaction li~uid, WA~~h~t~ with an aqueous saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Active car~on was ~e~ to the solution. The solution was ~iltered, and the solvent was remo~ed ~y distillation to o~tain 102 mg (13~) o~
2,3-diethyl-1,4-benzenecarbaldehyde in a colorless prism crystal state.
Melting point 32.0-34.5~C
High resolution mass speatrum as Cl2~l4o2 Calculated: 190.0994 Found: 190.0990 Experimental ~YA~rle 1 HeLa Cell Growth Inhibition Activity:
~ eLa S3 cells were maintA; nr~r~ as a monolayer culture in Eagle's m;n;~~l medium (Nissui Seiyaku ~.R., Tokyo) con~aining 2mM glu~mine, lQQ ~g/m~ of k~~A~y~in sulfa~, a~d 10~ inactivated fetal calt ~erum at 37~C in a carbon dio~ide incubator. The cells 1.8x10 were inoculated to a 96-well plate, and were exposed to the test compounds ~rom the ne~t day ~or 72 hours. Then, the viable cell ~cr~ were measured by evaluating the ability to reduce 3-~4,5-~;methylthiA~1-2-yl]-2,5-~;~h~nyltetrazolium bromi de ~MTT) according to the Mosmann's method (Mo~nn,T., J, T ~1, Meth., 65, 55-63?
1983~. Table 1 8how8 the cell growth inhibition activities as a 50~ ;nh;b;tion co~centration which i8 ~ Ated from the dep~n~nc~ o~ the ratio o~ growth of the co_~ound-treated cells to the growth o~ non-treated cell~ on the compo,und concentration.
E~a~mental r _le 2 Antitumor ef~ect in Colon 26-bearin~ _ice:
Colon 26 cells lx106 were transplanted into an AY; 1 1 ~ry region of 8-week old CDFl female mice (Japan SLC
Inc., ~m~tsu) subcutaneously. Si_ days after the transplantation, when the tumor grew palpable, the compound wa~ A~~i ni stered via the tail vein. One week a~ter the A~mi n; stration, the tumor wa~ removed and weighed. The antitu~or activity was represented by tumor growth inhibition rate (TGI~ =
(1 - TJC)xlOO) derived from the ratio (T/C) o~ the average tumor weight ~T~ of the compound-administered ~roup to the average tumor weight (C) of the control group. Table 1 shows the tumor growth inhibition rate.
Table 1 shows also the che_otherapy inde~
(MTD/TGI50) de~ined by the ratio o~ the m~ lm tolerant dose ~or the mice (M~D, mg/kg) to the do~e (TGI50, m~/kg) at which the tumor growth inhibition rate (TGI) i5 50% in colon26-bearing mice.

q!~le 1 Cell ~rowth Antitumor Chemotherapy E~ample inhibition aativity ;nA~Y
No.
~eLa 83 Colon-26 M~D/TGIso IC50 ~ng/mL) TGI~ (~g/kg) 1 0.0031 92 (7.81) 21.9 3 0.00934 4 0.00276 91 (0.488) 9 0.00595 90 (1.95) 6 0.0318 . - -8 0.00158 89 (0.977) 4.6 0.011 85 (0.977) 7.4 13 0.0198 88 (~.91) 3.6.
18 0.000459 19 0.0134 0.0716 - -21 0.0003~ - -22 0.0227 As shown above, the compounds o~ the present invention ~yh;hited exc~llent antitumor activity.

Industrial Applicability The compounds o~ the present invention have e~cellent antimicrobial activity and antitumor activity, and yet exhibit high seleGtivity to c~nC~ cells, and are less toxic. The com~ounds o~ the present invention have high cell-killing activity, and antitumor~ activity o~er a wide sa~e region There~ore, the compo~nds are e~ecti~e to tumors having lowered susceptibilit~ to antitumor medicines, and is promising to mitigate the burden o~ chemotherapy on cancer patients.

Claims (3)

What is claimed is:
1. Acrylamide derivatives represented by General Formula (1):

(1) (wherein X1 and X2 are independently a hydrogen atom, a halogen atom, an amino group, an alkylamino group, an aminoalkyl group, a hydroxyl group, OR3 (R3 being a linear or branched lower alkyl of C1-C6, or a substituted or unsubstituted aryl), OCOR3 (R3 being the same as above), or a linear or branched lower alkyl of C1-C6, and X1 and X2 may be linked together; the ring A is a pyrrole ring, a furan ring, a thiophene ring, a benzene ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a biphenyl ring, a bipyridine ring, a bipyrimidine ring, a naphthalene ring, an anthracene ring, or an anthraquinone ring; and R1 and R2 are independently:
a.

(R4 is a hydrogen atom a protecting group for hydroxyl, or a substituent decomposable in vivo; Y is a halogen atom, an arylsulfonyloxy group, a lower alkylsulfonyloxy group, a haloalkylsulfonyloxy group, or an azide group;
is a condensed ring, or ; or b.

is a condensed ring or ;
or an optical isomer thereof, or a pharmaceutically acceptable salt thereof.
2. A process for producing a compound of General Formula (3):

(3) wherein X1 and X2 are independently a hydrogen atom, a halogen atom, an amino group, an alkylamino group, an aminoalkyl group, a hydroxyl group, OR3 (R3 being a linear or branched lower alkyl of C1-C6, or a substituted or unsubstituted aryl), OCOR3 (R3 being the same as above), or a linear or branched lower alkyl of C1-C6, and X1 and X2 may be linked together; the ring A is a pyrrole ring, a furan ring, a thiophene ring, a benzene ring, a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a biphenyl ring, a bipyridine ring, a bipyrimidine ring, a naphthalene ring, an anthracene ring, or an anthraquinone ring; R6 and R7 are independently (R4 being a hydrogen atom, a protecting group for hydroxyl, or a substituent decomposable in vivo; Y being a halogen atom, an arylsulfonyloxy group, a lower alkylsulfonyloxy group, a haloalkylsulfonyloxy group, or an azide group;
being a condensed ring, or ; or being a condensed ring, or :
the process comprising acylating a compound of General Formula, or a salt thereof:

where R4, Y, and are as defined above, or where is as defined above, with dicarboxylic acid derivatives represented by General Formula (2):

(2) where X1, X2, and the ring A are as defined above, and R5 is OH or a reactive residue.
3. Acrylamide derivatives, an optically active isomer, or a pharmaceutically acceptable salt thereof as set forth in claim 1, wherein and are represented by any of the formulas below:

CA002205872A 1994-11-29 1995-11-28 Acrylamide derivatives and process for production thereof Abandoned CA2205872A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPHEI6-295274 1994-11-29
JP29527494 1994-11-29

Publications (1)

Publication Number Publication Date
CA2205872A1 true CA2205872A1 (en) 1996-06-06

Family

ID=17818480

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205872A Abandoned CA2205872A1 (en) 1994-11-29 1995-11-28 Acrylamide derivatives and process for production thereof

Country Status (12)

Country Link
US (1) US5786486A (en)
EP (1) EP0799827B1 (en)
KR (1) KR100395083B1 (en)
CN (1) CN1051552C (en)
AT (1) ATE266663T1 (en)
AU (1) AU693283B2 (en)
CA (1) CA2205872A1 (en)
DE (1) DE69533043T2 (en)
FI (1) FI972074A0 (en)
HU (1) HUT77654A (en)
MX (1) MX9703917A (en)
WO (1) WO1996016965A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742641B2 (en) 1998-01-28 2002-01-10 Shionogi & Co., Ltd. Novel tricyclic compound
EP1434778A4 (en) * 2001-05-31 2005-07-13 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
BRPI0510909A2 (en) * 2004-05-19 2008-12-16 Medarex Inc cytotoxic drug-binder binding compound, pharmaceutical formulation, method for killing a cell and method for retarding or stopping tumor growth
RU2402548C2 (en) * 2004-05-19 2010-10-27 Медарекс, Инк. Chemical linkers and conjugates thereof
WO2006089230A2 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
DK1940789T3 (en) 2005-10-26 2012-03-19 Medarex Inc Methods and Compounds for the Preparation of CC-1065 Analogs
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
TWI412367B (en) 2006-12-28 2013-10-21 Medarex Llc Chemical linkers and cleavable substrates and conjugates thereof
CA2678514A1 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
ES2960619T3 (en) 2014-02-28 2024-03-05 Hangzhou Dac Biotech Co Ltd Loaded Linkers and Their Uses for Conjugation
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR102459468B1 (en) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1238907A (en) * 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
JP2598819B2 (en) * 1986-12-19 1997-04-09 ジ・アップジョン・カンパニー New CC-1065 homologs
EP0520435A3 (en) * 1991-06-28 1993-05-05 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivatives
JP2502005B2 (en) 1992-04-27 1996-05-29 オンキヨー株式会社 Biofeedback system
JP3514490B2 (en) * 1992-08-21 2004-03-31 杏林製薬株式会社 Trifluoromethylpyrroloindole carboxylate derivative and method for producing the same

Also Published As

Publication number Publication date
AU3937095A (en) 1996-06-19
ATE266663T1 (en) 2004-05-15
EP0799827A4 (en) 1998-01-28
DE69533043T2 (en) 2005-04-07
AU693283B2 (en) 1998-06-25
WO1996016965A1 (en) 1996-06-06
CN1174553A (en) 1998-02-25
US5786486A (en) 1998-07-28
DE69533043D1 (en) 2004-06-17
CN1051552C (en) 2000-04-19
EP0799827B1 (en) 2004-05-12
KR100395083B1 (en) 2004-02-05
FI972074A0 (en) 1997-05-14
HUT77654A (en) 1998-07-28
EP0799827A1 (en) 1997-10-08
MX9703917A (en) 1998-05-31

Similar Documents

Publication Publication Date Title
EP0269025B1 (en) Rebeccamycin analogs
CA2205872A1 (en) Acrylamide derivatives and process for production thereof
KR100312445B1 (en) Producing process of trifluoromethylpyroloindolecarboxylic acid ester
US5736549A (en) Hypoxanthine and guanine compounds
EP2240494B1 (en) Thieno-pyridine derivatives as mek inhibitors
EP1067933B1 (en) Semi-synthetic ecteinascidins
WO2017202390A1 (en) Heterocyclic compound serving as fgfr4 inhibitor
EP0070562B1 (en) Ergoline derivatives, processes for their preparation and pharmaceutical compositions containing them
ES2665546T3 (en) Synthesis of Triazolopyrimidine Compounds
BE1004069A3 (en) Novel iso-indole and their salts, methods of making and tumor agents including.
HU205358B (en) Process for producing pyrrolopyrimidines and pharmaceutical compositions comprising such compounds
US4490366A (en) 2'-Deoxy-5-fluorouridine derivative and a process for producing the same and an antitumor agent comprising the same
EP0468400A1 (en) DC-89 derivatives as antitumoral agents
CA2153905A1 (en) Propenone derivatives
FI88160B (en) FOER FARING FOR THERAPEUTIC TREATMENT OF ANALYZED ISOXAZOLYL-CARBOLINER
CN115772159A (en) KIF18A inhibitors
US5214065A (en) Dc-89 derivatives
CN115785068A (en) KIF18A inhibitors
KR100676114B1 (en) Polycyclic compounds having anti-tumor activity
JP4038245B2 (en) Novel phenanthridinium derivatives
US5248692A (en) DC-89 derivatives as anti-tumor agents
US9102683B2 (en) Heterocyclic compounds
JP3459270B2 (en) Preparation of N-tert-butoxycarbonyl-maleimide
JP3759772B2 (en) Acrylamide derivative and method for producing the same
JPH06501922A (en) Tricyclo compounds, their production methods, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued